Lynn D. Hudson

Dr. Lynn D. Hudson

Chief Science Officer for the Critical Path Institute (C-Path) and Executive Director of the Multiple Sclerosis Outcome Assessments Consortium

Dr. Lynn D. Hudson serves as the Chief Science Officer for the Critical Path Institute (C-Path) and Executive Director of the Multiple Sclerosis Outcome Assessments Consortium. She started at C-Path by overseeing the first regulatory qualification of an imaging biomarker for patient enrichment in clinical trials for Alzheimer’s disease. Recent collaborative efforts include launching the International Neonatal Consortium. Lynn graduated with a B.S. in Biochemistry from the University of Wisconsin and a Ph.D. in Genetics and Cell Biology from the University of Minnesota, and trained at Harvard Medical School and Brown University. As Chief of the Developmental Genetics Section at the National Institute of Neurological Disorders and Stroke, she conducted research to define the network of genes involved in neural development. She served as an officer for the American Society for Neurochemistry and the PMD Foundation, and as an advisor for a number of granting agencies, including NIH, NSF, and the National MS Society. At the National Institutes of Health, Lynn directed the Office of Science Policy Analysis from 2006-2011. Presently Lynn represents C-Path on the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation, and on the board of BIOSA, the Bioindustry Organization of Southern Arizona. She has a Research Professor appointment in the College of Medicine at the University of Arizona, and was honored by AZBIO as the 2015 Arizona Bioscience Leader of the Year.

BACK

2015-10-16T10:45:08+00:00